## BBY: Best Buy Co., Inc. - XLY: Consumer Cyclical

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($67.70)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Brown Advisory Inc. Lowers Stake in Best Buy Co., Inc. $BBY**
- Source: MarketBeat | 20251208T090816 | Neutral | Relevance: 98%
-  Brown Advisory Inc. reduced its stake in Best Buy Co., Inc. (NYSE:BBY) by 25.6% during the second quarter, selling 71,251 shares and now owning 206,813 shares valued at approximately $13.88 million. Despite this, Best Buy exceeded Q2 earnings expectations with $1.40 EPS and $9.67 billion revenue, and analysts currently rate the stock as "Hold" with an average price target of $84.74. The company also announced a quarterly dividend of $0.95, resulting in a 5.1% yield, and insiders have sold a significant amount of shares in the past three months.

**2. Best Buy appoints lululemon CFO Meghan Frank to board of directors**
- Source: Investing.com | 20251209T090500 | Somewhat-Bullish | Relevance: 98%
- Best Buy Co., Inc. has appointed Meghan Frank, CFO of lululemon, to its Board of Directors, effective immediately. Frank brings over 20 years of experience in finance, merchandise planning, and retail, which is expected to be a key addition to Best Buy's governance structure as it adapts its retail strategy. This appointment follows Best Buy's strong financial performance, including a notable increase in second-quarter comparable sales and consistent dividend payments.

**3. Bed Bath & Beyond & Brand House Collective Announce Chief of Stores**
- Source: Home Furnishings Business | 20251208T010912 | Somewhat-Bullish | Relevance: 98%
-  Bed Bath & Beyond, Inc. and The Brand House Collective, Inc. have appointed Glen Cary as Chief of Stores for Bed Bath & Beyond and its associated brands. Cary brings over 25 years of retail leadership experience, including previous roles at Bed Bath & Beyond and buybuy BABY, to drive retail sales, strengthen operational discipline, and modernize the store fleet. The leadership team expects Cary to deliver exceptional in-store experiences and significant growth for the brands.

**4. SVB Wealth LLC Sells 16,290 Shares of Best Buy Co., Inc. $BBY**
- Source: MarketBeat | 20251209T142544 | Neutral | Relevance: 97%
-  SVB Wealth LLC significantly reduced its stake in Best Buy Co., Inc., selling 16,290 shares and now owning 23,772 shares valued at approximately $1.596 million. This follows substantial insider selling, with Best Buy Chairman Richard M. Schulze selling 74,553 shares for $6.29 million and other insiders selling roughly $126.6 million worth of shares in the last 90 days. Despite the insider sales, Best Buy reported strong quarterly earnings, beating estimates and providing positive FY2026 EPS guidance, alongside announcing a quarterly dividend of $0.95 per share.

**5. Best Buy Co., Inc. $BBY Shares Bought by Epoch Investment Partners Inc.**
- Source: MarketBeat | 20251206T095410 | Somewhat-Bullish | Relevance: 97%
-  Epoch Investment Partners Inc. increased its stake in Best Buy Co., Inc. by 3.5% in the second quarter, now owning 624,135 shares valued at $41.898 million. Other institutional investors like LPL Financial LLC and Blair William & Co. IL also adjusted their holdings. Analysts have a "Hold" consensus rating with a target price of $84.74.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 7, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | Truist Securiti | $84 | $79 | +6% |
| 2025-11-26 | Barclays | $81 | $74 | +9% |
| 2025-11-26 | UBS | $96 | $93 | +3% |
| 2025-11-26 | Morgan Stanley | $82 | $75 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | Truist Securiti | main | Hold |
| 2025-11-26 | Barclays | main | Equal-Weight |
| 2025-11-26 | UBS | main | Buy |
| 2025-11-26 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 8 ($109.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 11.8% (-0.5%)
- Vanguard Group Inc: 11.4% (+2.4%)
- State Street Corpora: 6.3% (-2.2%)
- JPMORGAN CHASE & CO: 4.5% (+74.1%)
- Charles Schwab Inves: 3.5% (+3.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $110M sold (8 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 7 raises (avg +7%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Quality metrics strong (ROE 22%). Analyst sentiment positive (7 raises, avg +7%). Insider selling cluster ($109.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.3B |
| Beta | 1.39 |
| 52W Range | $54.99 - $91.68 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 10.8 |
| Current P/E | 11.4 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -4.7% to -6.6% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.6pp (needs >4.0% for momentum thesis). AM_20 at -4.7% indicates price below own 20MA trend. Underperforming sector by 5.8pp, stock-specific weakness. Below SMA200 (1.00x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.58% (CS: 6) | Weak |
| RSI_14 | 37.0 | Neutral |
| MACD Histogram | -0.41 | Bearish |
| vs SMA20 | 0.954x | Below |
| vs SMA50 | 0.931x | Below |
| vs SMA200 | 0.996x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $72.56
- **Stop Loss:** $67.70 (6.7% risk)
- **Target:** $82.28 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $7,401.12
- **Portfolio %:** 7.40%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-03-03 (Est: $2.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.40 | +6.7% |
| 2025Q3 | $1.22 | $1.28 | +4.5% |
| 2025Q2 | $1.10 | $1.15 | +5.0% |
| 2025Q1 | $2.41 | $2.58 | +7.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*